US FDA denies Teva's plea to reject generic Copaxone apps
This article was originally published in Scrip
Executive Summary
Investors on 9 June were ambiguous about what the US FDA's latest denial of a citizen petition filed by Teva late last year may mean for the firm's multiple sclerosis drug Copaxone (glatiramer acetate) and the generic competitors the Israeli drug maker has been trying to keep off the US market.